Core Viewpoint - The company is expected to achieve a net profit of 170 million to 185 million yuan in the first half of 2025, reflecting a year-on-year growth of 13.92% to 23.97%, maintaining its leading position in the field of allergic disease treatment [1] Group 1: Product Performance - The core product "Dust Mite Drops" continues to show strong growth, with sales revenue reaching 455 million yuan, a year-on-year increase of 10.51% [2] - The sales revenue of "Artemisia Pollen Allergen Sublingual Drops" is 21 million yuan, growing by 71.37% year-on-year, while "Skin Prick Test Solution" sales reached 6.3 million yuan, up 104.38% year-on-year, driven by increased market promotion efforts [2] Group 2: Innovation and R&D - The company is increasing its investment in innovative R&D, with multiple projects making significant progress, including the expansion of its allergen product pipeline [3] - New products such as "Sycamore Pollen Allergen Skin Prick Solution" and "German Cockroach Allergen Skin Prick Solution" have received approval for market application, enhancing the product pipeline [3] Group 3: Industry Environment - The incidence of allergic diseases is rising in China, driven by increased health awareness and environmental changes, leading to growing medical demand and technological advancements in the field [4] - The "Healthy China 2030" strategy emphasizes the prevention and treatment of allergic diseases, with desensitization therapy recognized as a key method, promoting clinical application and market expansion of related products [4] Group 4: Operational Quality - The company has optimized production processes and strengthened cost control, maintaining a high level of profitability and improving operational cash flow, indicating good financial health [5] - The company plans to continue focusing on the allergic disease field and accelerate the launch of in-development products, with expectations for sustained growth in performance [5] Group 5: Overall Performance Outlook - The company's performance in the first half of 2025 aligns with market expectations, showcasing resilience and a promising future driven by core product growth and innovation strategies [6]

Core Insights - The pollen allergy season in Inner Mongolia has arrived earlier this year, peaking around August 10, approximately half a month earlier than previous years [3][5] - The increase in allergy cases is attributed to abundant rainfall this summer, which has promoted the growth of allergenic plants like mugwort and ragweed, leading to higher pollen concentrations [3][5] Patient Experience - Many patients are experiencing severe symptoms, including persistent sneezing, itchy eyes, and difficulty breathing, with some resorting to daily monitoring of pollen levels [3][5] - The demand for medical consultations has surged, with doctors reporting nearly 100 patients per day, predominantly suffering from mugwort pollen allergies [3][5] Treatment and Prevention - Effective treatment for allergic rhinitis requires regular and standardized medical care, as many patients report ineffective results due to improper treatment [5] - Physical protection measures are recommended, such as avoiding high pollen areas and using high-grade masks or nasal filters [5] - Preventive medication should be started at least a month before the allergy season to significantly reduce symptoms [5] Community Action - The incidence of allergic diseases is rising in Inner Mongolia, particularly among children and adolescents, prompting local governments to take action against allergenic plants [7] - Various regions in Inner Mongolia are actively removing mugwort, with significant areas cleared to alleviate allergy burdens [7] - Community initiatives are encouraged to involve citizens in the removal of allergenic plants to protect the health of allergic individuals [7]